OncoMatch/Clinical Trials/NCT07176689
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Is NCT07176689 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Nirogacestat for desmoid tumor.
Treatment: Nirogacestat — This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: gamma secretase inhibitor
previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy
Cannot have received: anti-Notch antibody therapy
previously received or is currently receiving gamma secretase inhibitors or anti-Notch antibody therapy
Cannot have received: tyrosine kinase inhibitor
currently using any treatment for DT/AF including tyrosine kinase inhibitors (TKIs) or any investigational treatment 28 days (or 5 half-lives, whichever is longer) prior to the first dose of study treatment
Cannot have received: hormonal contraception or ovarian suppression
currently using or has used hormonal contraception or ovarian suppression within 90 days prior to first dose of study treatment
Lab requirements
Blood counts
adequate organ and bone marrow function required
Kidney function
adequate organ and bone marrow function required
Liver function
adequate organ and bone marrow function required; known hepatic impairment excluded
adequate organ and bone marrow function; known hepatic impairment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify